| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/12/2005 | CA2113813C Immunoglobulin variants for specific fc epsilon receptors |
| 04/12/2005 | CA2108292C Process for preparing hepatitis a (hav) antigens and vaccines |
| 04/12/2005 | CA2091354C Treatment of inflammation |
| 04/12/2005 | CA2086672C Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| 04/12/2005 | CA1341479C Hybrid single-chain plasminogen activators |
| 04/08/2005 | CA2445743A1 Methods for modulating neuronal responses |
| 04/07/2005 | WO2005030969A1 Method for mass production of human follicle stimulating hormone |
| 04/07/2005 | WO2005030951A1 Royal jelly peptide and composition containing the same |
| 04/07/2005 | WO2005030804A2 A method of modulating cell survival, differentiation and/or synaptic plasticity |
| 04/07/2005 | WO2005030803A1 Therapeutic molecules |
| 04/07/2005 | WO2005030802A2 Antigens for an east coast fever vaccine |
| 04/07/2005 | WO2005030801A1 A novel conotoxin modulating sodium channels |
| 04/07/2005 | WO2005030797A2 Melanocortin receptor agonists |
| 04/07/2005 | WO2005030796A1 Macrocyclic inhibitors of hepatitis c virus ns3 serine protease |
| 04/07/2005 | WO2005030795A1 Amidomethyl substituted 1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-n-acetic acid derivatives, process and intermediate products for their preparation and medicaments containing these compounds |
| 04/07/2005 | WO2005030794A2 Hemiasterlin derivatives and uses thereof |
| 04/07/2005 | WO2005030790A1 Novel triterpene derivatives, preparation thereof and use thereof |
| 04/07/2005 | WO2005030787A2 Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
| 04/07/2005 | WO2005030261A1 Oncolytic adenoviral vectors encoding gm-csf |
| 04/07/2005 | WO2005030258A2 Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| 04/07/2005 | WO2005030248A1 Clostridium botulinum c3 exotransferase compositions and methods for treating tumour spreading |
| 04/07/2005 | WO2005030246A1 Novel use of antisecretory factor |
| 04/07/2005 | WO2005030245A1 Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases |
| 04/07/2005 | WO2005030244A1 Agent for promoting osteogenesis and/or inhibiting bone resorption |
| 04/07/2005 | WO2005030243A1 Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
| 04/07/2005 | WO2005030242A1 Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
| 04/07/2005 | WO2005030241A2 Treating inflammation using a biological agent that causes cells to release cytokine receptors |
| 04/07/2005 | WO2005030240A2 Vege-cor vege-d materials and methods for stimulation of neural stem cells |
| 04/07/2005 | WO2005030239A2 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
| 04/07/2005 | WO2005030238A1 Peptides having, for example, an antiangiogenic activity and applications thereof in therapeutics |
| 04/07/2005 | WO2005030205A1 Ocular solutions containing a macrolide antibiotic and/or mycophenolic acid |
| 04/07/2005 | WO2005030196A2 Methods of treating autoimmune diseases using il-21 |
| 04/07/2005 | WO2005030190A1 Natural menaquinone 7 compositions |
| 04/07/2005 | WO2005030154A1 Composition for treating bad breath |
| 04/07/2005 | WO2005030136A2 Tumor vaccine |
| 04/07/2005 | WO2005030133A2 Treatment with agonists of toll-like receptors |
| 04/07/2005 | WO2005030132A2 Therapeutic regimens for administering drug combinations |
| 04/07/2005 | WO2005030126A2 Adhesin-specific nanoparticles and process for using same |
| 04/07/2005 | WO2005030119A2 Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
| 04/07/2005 | WO2005018657A3 NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY |
| 04/07/2005 | WO2005016960A3 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 04/07/2005 | WO2005012305A3 Tricyclic parp inhibitors |
| 04/07/2005 | WO2005010024A3 Potent peptide inhibitors and methods of use |
| 04/07/2005 | WO2005009415A3 Novel method for microparticles production |
| 04/07/2005 | WO2005007676A3 Glycopeptides for the treatment of als and other metabolic and autoimmune disorders |
| 04/07/2005 | WO2005000893A3 Pharmaceutical composition comprising cyclic somatostin analogues |
| 04/07/2005 | WO2005000195A3 A pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger |
| 04/07/2005 | WO2004110245A3 Combination therapy for cancer treatment |
| 04/07/2005 | WO2004108948A3 Systems, methods and kits for characterizing phosphoproteomes |
| 04/07/2005 | WO2004105791A3 Recombinant anti-lhrh vaccines |
| 04/07/2005 | WO2004096976A3 Spex compositions and methods of use |
| 04/07/2005 | WO2004092207A3 Respiratory syncytial virus (rsv) peptides |
| 04/07/2005 | WO2004091498A3 Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| 04/07/2005 | WO2004074446A3 Parkin interacting polypeptides and methods of use |
| 04/07/2005 | WO2004073741A8 Remedy for spinal injury containing interleukin-6 antagonist |
| 04/07/2005 | WO2004066953A3 Polymerized hemoglobin solutions having reduced amount of tetramer and method for preparing |
| 04/07/2005 | WO2004066947A3 Hyperthermia oncolysis co-therapy |
| 04/07/2005 | WO2004060322A3 Pharmaceutical preparations for treatments of diseases and disorders of the breast |
| 04/07/2005 | WO2004030618A3 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| 04/07/2005 | WO2004007695A3 Lactobacilli expressing biologically active polypeptides and uses thereof |
| 04/07/2005 | WO2004002422A3 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 04/07/2005 | WO2004001072A3 Method for diagnosis of colorectal tumors |
| 04/07/2005 | WO2003093452A3 Variants of nedd4l associated with hypertension and viral budding |
| 04/07/2005 | WO2003093293A3 Peptide antagonists of tgf-beta family members and therapeutic uses thereof |
| 04/07/2005 | WO2003092593A3 Tumor suppressor gene polypeptides |
| 04/07/2005 | WO2003090689A3 Neurodegenerative disorder treatment using gdnf secreting neural cells |
| 04/07/2005 | WO2003082081A3 Use of rom production and release inhibitors to treat and prevent intraocular damage |
| 04/07/2005 | WO2003072724A3 Human analogs of murine deubiquitinating protease genes |
| 04/07/2005 | WO2003065981A3 Therapeutic use for lp229, in particular for wound healing |
| 04/07/2005 | WO2003064458A8 Novel peptide derivatives, preparation and therapeutic and cosmetic application thereof |
| 04/07/2005 | WO2003063688A3 Protein modification and maintenance molecules |
| 04/07/2005 | WO2003057711A3 Isolated cytokine receptor licr-2 |
| 04/07/2005 | WO2002045659A3 Novel therapeutics for heart failure and aging |
| 04/07/2005 | US20050076395 Transgenic mouse comprising nucleotide sequences coding immunoglobulin domains j, c, v and d for use as bioreactor in biosynthesis of human antibodies; immunodiagnostics |
| 04/07/2005 | US20050075485 Neisseria meningitidis antigen |
| 04/07/2005 | US20050075484 Construction and use of synthetic constructs encoding syndecan |
| 04/07/2005 | US20050075483 Vancomycin derivatives linked with disaccharide sugar, obtained by deprotecting a protected glycopeptide, by sulfonation, replacement; preparing a glycopeptide by glycosylation of an aglycone derived from glycopeptide antibiotic |
| 04/07/2005 | US20050075481 T cell epitopes of the cyn d 1 allergen from bermuda grass pollen |
| 04/07/2005 | US20050075480 Urotensin-II agonists and antagonists |
| 04/07/2005 | US20050075397 Composition comprising at least one alkanolamide for inhibiting langerhans cells migration, and uses thereof |
| 04/07/2005 | US20050075396 Modulation of type 2 diabetes and drug delivery |
| 04/07/2005 | US20050075380 Composition comprising at least one oxazolin for inhibiting langerhans cell migratio, and uses thereof |
| 04/07/2005 | US20050075338 5-(Substituted oxazolyl- or thiazolyl-ethoxy)indaneacetic acid derivatives, used in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases |
| 04/07/2005 | US20050075314 Using pharmaceutical preparation of mucopolysaccharides having an anticoagulant activity of <100 BP units/mg for prophylactic priming or curative treatment of the cervix and the myometrium; sulfates of heparin chondroitin and dermatan and their depolymerized products |
| 04/07/2005 | US20050075313 Ophthalmic compositions containing galactomannan polymers and borate |
| 04/07/2005 | US20050075304 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| 04/07/2005 | US20050075302 Administering a phosphorothioate oligonucleotide analog by inhalation, ophthalmic, intranasal, parenteral, oral or intradermal , wherein the phosphorothioate oligonucleotide analog is not antisense; anticarcinogenic and - tumor agents;surgical infections; immunopotentiation; O-alkyl modified |
| 04/07/2005 | US20050075301 Pharmaceutical preparation with RNA as hemostasis cofactor |
| 04/07/2005 | US20050075299 Antisense modulation of wrn espression |
| 04/07/2005 | US20050075298 Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
| 04/07/2005 | US20050075293 Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents |
| 04/07/2005 | US20050075292 synergistic administration of a Beta Defensin agent, a beta defensin inducing agent, and potentiators between a BD-polypeptide and a chemokine receptor and a HIV virion; viricides for chemokine receptor-associated viruses |
| 04/07/2005 | US20050075291 mixture of anticoagulants and a protein C or activated protein C polypeptide comprising a modified gamma -carboxyglutamic acid (GLA) domain to enhance membrane binding receptivity, used for modulation of coagulation in mammals |
| 04/07/2005 | US20050075290 For drug screening pituitary adenylate cyclase activating peptide (PACAP)/vasoactive intestinal peptide (VIP) receptor antagonists; oral/nasal/intravenous/arterial administration |
| 04/07/2005 | US20050075289 coagulation proteins or polypeptides having specific predetermined patterns of asparagine-linked (N-linked) oligosaccharides, used for treating a Factor VII-responsive syndromes such as haemophilia, Factor XI deficiency, Factor VII deficiency, thrombocytopenia, von Willebrand's disease; blood disorders |
| 04/07/2005 | US20050075288 Pharmaceutical and cosmetic compositions comprising plgf-1 |
| 04/07/2005 | US20050075287 Use of erythropoietin for the preventive or curative treatment of cardiac failure |
| 04/07/2005 | US20050075285 compounds effective for reducing cholesterol levels, body fat, and body mass, and useful for treating metabolic-related diseases and disorders |
| 04/07/2005 | US20050075284 peptide analogues or conjugates of vasoactive intestinal peptide(VIP), used for vaginal relaxation and/or for modulation of sperm motility |
| 04/07/2005 | US20050075281 Acylated nonadepsipeptides |